Manual Washington de especialidades clínicas. Endocrinología

Capítulo 32 Diabetes monogénica   311

RE F ERENC I AS 1. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity- onset diabetes of the young. N Engl J Med 2001;345(13):971–980. 2. Temple IK, Gardner RJ, Mackay DJ, Barber JC, Robinson DO, Shield JP. Transient neo- natal diabetes: Widening the understanding of the etiopathogenesis of diabetes. Diabetes 2000;49(8):1359–1366. 3. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350(18):1838–1849. 4. Babenko AP, Polak M, Cavé H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006;355(5):456–466. 5. Pearson ER, Flechtner I, Njølstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355(5):467–477. 6. Carmody D, Støy J, Greeley SAW, et al. Chapter 2: A clinical guide to monogenic diabetes. In: Weiss RE, Refetoff S, eds. Genetic Diagnosis of Endocrine Disorders . 2nd ed. Waltham, MA: Academic Press; 2016:21–30. 7. Naylor R, Philipson LH. Who should have genetic testing for maturity-onset diabetes of the young? Clin Endocrinol (Oxf) 2011;75(4):422–426. 8. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): How many cases are we missing? Diabetologia 2010;53(12):2504–2508. 9. Chakera AJ, Spyer G, Vincent N, Ellard S, Hattersley AT, Dunne FP. The 0.1% of the population with glucokinase monogenic diabetes can be recognized by clinical characteristics in pregnancy: The Atlantic Diabetes in Pregnancy cohort. Diabetes Care 2014;37(5):1230–1236. 10. Iafusco D, Massa O, Pasquino B, et al. Minimal incidence of neonatal/infancy onset diabetes in Italy is 1:90000 live births. Acta Diabetol 2012;49(5):405–408. 11. Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes 1975;24(1):44–53. 12. Naylor RN, et al. Monogenic Diabetes: Maturity-Onset Diabetes of the Young (MODY) and Neonatal Diabetes. In: Draznin B, ed. Atypical Diabetes . Arlington, VA: American Diabetes Association; 2018:3–36. 13. Steele AM, Wensley KJ, Ellard S, et al. Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: observational case control studies. PLoS One . 2013;8(6):e65326. Available at: https://doi.org/10.1371/journal.pone.0065326. Accessed November 30, 2018. 14. McDonald TJ, Colclough K, Brown R, et al. Islet autoantibodies can discriminate maturity- onset diabetes of the young (MODY) from type 1 diabetes. Diabet Med 2011;28(9):1028–1033. 15. Ludvigsson J, Carlsson A, Forsander G, et al. C-peptide in the classification of diabetes in chil- dren and adolescents. Pediatr Diabetes 2012;13(1):45–50. 16. BesserRE,ShepherdMH,McDonaldTJ,etal.UrinaryC-peptidecreatinineratioisapracticaloutpa- tienttoolforidentifyinghepatocytenuclearfactor1-alpha/hepatocytenuclearfactor4-alphamaturity- onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 2011;34(2): 286–291. 17. Menzel R, Kaisaki PJ, Rjasanowski I, Heinke P, Kerner W, Menzel S. A low renal threshold for glucose in diabetic patients with a mutation in the hepatocyte nuclear factor-1alpha (HNF- 1alpha) gene. Diabet Med 1998;15(10):816–820. 18. McDonald TJ, Shields BM, Lawry J, et al. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes. Diabetes Care 2011;34(8):1860–1862. 19. American Diabetes Association. 3. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2018. Diabetes Care . 2018;41(Suppl 1): S28–S37. 20. Stein SA, Maloney KL, Pollin TI. Genetic counseling for diabetes mellitus. Curr Genet Med Rep 2014;2(2):56–67. 21. Bingham C, Hattersley AT. Renal cysts and diabetes syndrome resulting from mutations in hepatocyte nuclear factor-1beta. Nephrol Dial Transplant 2004;19(11):2703–2708. 22. Stride A, Shields B, Gill-Carey O, et al. Cross-sectional and longitudinal studies suggest phar- macological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia 2014;57(1):54–56. AMPLE